Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
ZN-c3 + Gemcitabine in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Brandon Huffman
- Target Recruit Count
- 34
- Registration Number
- NCT06015659
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 27
- Registration Number
- NCT06001658
- Locations
- 🇺🇸
SKCCC Johns Hopkins, Baltimore, Maryland, United States
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT05999994
- Locations
- 🇧🇪
UCL- Saint Luc, Bruxelles, Belgium
🇫🇷Institut Curie, Paris, France
🇳🇱Prinses Maxima Centrum, Utrecht, Netherlands
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 10
- Registration Number
- NCT05984602
- Locations
- 🇺🇸
NYU Langone Ambulatory Care Center East 38th Street, New York, New York, United States
🇺🇸Ambulatory Care Center, New York, New York, United States
🇺🇸Clinical Cancer Center, New York, New York, United States
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2023-08-08
- Target Recruit Count
- 170
- Registration Number
- NCT05981001
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT05978609
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- CureLab Oncology
- Target Recruit Count
- 40
- Registration Number
- NCT05979298
- Locations
- 🇧🇾
Minsk City Clinical Oncology Center, Minsk, Belarus
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 64
- Registration Number
- NCT05975307
- Locations
- 🇨🇳
Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05967182
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Hummingbird Bioscience
- Target Recruit Count
- 68
- Registration Number
- NCT05919537
- Locations
- 🇦🇺
ICON Cancer Centre South Brisbane, Brisbane, Queensland, Australia
🇦🇺GenesisCare North Shore, Sydney, New South Wales, Australia
🇦🇺Southern Oncology Clinical Research Unit, Adelaide, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.